🔗 Share this article

Ministers and senior MPs have issued warnings that the United Kingdom's recent agreements with Washington are "lacking a solid foundation." This stems from revelations that a much-touted deal on drug pricing, which commits to zero tariffs in exchange for the NHS increasing its costs, lacks any detailed agreement beyond limited headline terms contained within government press releases.

An Agreement in Principle Only

The deal on drug tariffs, described as a "significant" achievement, is still an "broad understanding" without formal ratification. It has been highlighted that the public statements from the UK and US governments describe the deal in sharply different terms. The British version focuses on securing "zero per cent tariffs" as a unique achievement, while the American announcement dwells on the agreement for the NHS to pay higher prices for new medications.

"The danger exists that the UK government has made commitments to increase medicine costs in return for only a assurance from President Trump," commented David Henig, a trade policy analyst. "History shows he has a tendency for not keeping promises."

Broader Instability and a Paused Tech Deal

Anxieties have been intensified by Washington's recent decision to suspend the high-value digital accord, which was previously called "a generational step-change" in the bilateral relationship. The US claimed a failure to advance from the UK on lowering trade barriers as the reason for the pause.

Furthermore, concessions agreed to for British farmers as part of an earlier tariff deal have yet to be formally ratified by the US, despite a imminent January deadline. "Our understanding is that the US has not finalized the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Anxiety Behind Closed Doors

Behind the scenes, ministers have voiced worries that the government's US-UK accords are lacking substance. One minister was quoted as stating the series of agreements as "built on sand," while another framed the situation as the "current reality" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, chair of the health select committee, remarked: "What is even more astonishing than the US approach is the UK government's naive belief that his administration is a reliable partner. The NHS is not a bargaining chip."

Government Downplays Risks, Points to Gains

Government figures have downplayed the possibility of the US withdrawing from the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been lobbying for the agreement, wanting clarity on imports and pricing, making it of tangible value than the paused tech deal.

Officials admit that instability is part and parcel of dealing with the Trump administration. However, they maintain that the UK has achieved real benefits for businesses, such as reduced duties on automobiles compared to other nations. "Our achievement of 25% steel tariffs, which is lower than the rate for the rest of the world, is not flimsy," one official said.

Yet, problems have arisen in implementing the May tariff agreement. Promised reciprocal agricultural allowances have not materialized, and the pledge to "eliminate duties on UK metals" has is still pending, with tariffs staying at 25%.

As negotiations continue, the two sides have agreed to resume talks on the suspended digital agreement in January, following what were described as "very positive" meetings between UK and US officials in Washington.